JP2018525320A5 - - Google Patents

Download PDF

Info

Publication number
JP2018525320A5
JP2018525320A5 JP2017558673A JP2017558673A JP2018525320A5 JP 2018525320 A5 JP2018525320 A5 JP 2018525320A5 JP 2017558673 A JP2017558673 A JP 2017558673A JP 2017558673 A JP2017558673 A JP 2017558673A JP 2018525320 A5 JP2018525320 A5 JP 2018525320A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
amino acid
binding fragment
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017558673A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018525320A (ja
JP6857138B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/033153 external-priority patent/WO2016187354A1/en
Publication of JP2018525320A publication Critical patent/JP2018525320A/ja
Publication of JP2018525320A5 publication Critical patent/JP2018525320A5/ja
Application granted granted Critical
Publication of JP6857138B2 publication Critical patent/JP6857138B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017558673A 2015-05-18 2016-05-18 Axlタンパク質に結合する抗体 Active JP6857138B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562163264P 2015-05-18 2015-05-18
US62/163,264 2015-05-18
PCT/US2016/033153 WO2016187354A1 (en) 2015-05-18 2016-05-18 Antibodies that bind to axl proteins

Publications (3)

Publication Number Publication Date
JP2018525320A JP2018525320A (ja) 2018-09-06
JP2018525320A5 true JP2018525320A5 (cg-RX-API-DMAC7.html) 2019-06-20
JP6857138B2 JP6857138B2 (ja) 2021-04-14

Family

ID=57320780

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017558673A Active JP6857138B2 (ja) 2015-05-18 2016-05-18 Axlタンパク質に結合する抗体

Country Status (4)

Country Link
US (3) US10787516B2 (cg-RX-API-DMAC7.html)
EP (1) EP3297662A4 (cg-RX-API-DMAC7.html)
JP (1) JP6857138B2 (cg-RX-API-DMAC7.html)
WO (1) WO2016187354A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10787517B2 (en) * 2015-05-18 2020-09-29 Agensys, Inc. Antibodies that bind to AXL proteins
EP3297662A4 (en) * 2015-05-18 2019-03-13 Agensys, Inc. ANTIBODIES BINDING TO AXL PROTEINS
KR101909955B1 (ko) * 2016-11-28 2018-10-19 재단법인 목암생명과학연구소 신규 항-에이엑스엘 항체 및 이를 포함하는 약학적 조성물
WO2019051586A1 (en) * 2017-09-13 2019-03-21 National Research Council Of Canada AXL SPECIFIC ANTIBODIES AND USES THEREOF
CN110483639A (zh) 2018-05-15 2019-11-22 复旦大学 靶向axl的抗体及抗体-药物偶联物及其制备方法和用途
CN113045664B (zh) * 2019-11-28 2023-05-12 尚健单抗(北京)生物技术有限公司 一种分离的结合抗原axl的蛋白及其用途
WO2022197699A1 (en) * 2021-03-17 2022-09-22 Eli Lilly And Company Human tspan33 antibodies
EP4482861A2 (en) * 2022-02-24 2025-01-01 A & G Pharmaceutical, Inc. Fully human monoclonal antibodies against human progranulin

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
KR100845354B1 (ko) 2004-03-26 2008-07-09 화이자 프로덕츠 인코포레이티드 항-ctla-4 항체의 용도
JP2008515774A (ja) * 2004-08-03 2008-05-15 ダイアックス コーポレイション hK1結合タンパク質
SG186000A1 (en) * 2007-11-12 2012-12-28 U3 Pharma Gmbh Axl antibodies
CA2742968C (en) * 2008-11-07 2020-06-09 Fabrus Llc Combinatorial antibody libraries and uses thereof
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CA3018235C (en) 2009-03-20 2021-01-12 Amgen Inc. Carrier immunoglobulins and uses thereof
EP2430050A1 (en) * 2009-05-11 2012-03-21 U3 Pharma GmbH Humanized axl antibodies
AU2010305374A1 (en) 2009-10-09 2012-05-03 Sanofi Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
RU2577986C2 (ru) * 2010-06-18 2016-03-20 Дженентек, Инк. Антитела против axl и способы их применения
US9249228B2 (en) 2011-06-22 2016-02-02 Oribase Pharma Anti-Axl antibodies and uses thereof
CA2839480A1 (en) 2011-06-22 2012-12-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-axl antibodies and uses thereof
US20140121126A1 (en) 2012-10-25 2014-05-01 Memorial Sloan-Kettering Cancer Center Methods of detecting axl and gas6 in cancer patients
AR093357A1 (es) * 2012-11-05 2015-06-03 Pf Medicament Proteinas de union al antigeno y su utilizacion como producto de direccionamiento para el tratamiento del cancer
US10787517B2 (en) * 2015-05-18 2020-09-29 Agensys, Inc. Antibodies that bind to AXL proteins
EP3297662A4 (en) * 2015-05-18 2019-03-13 Agensys, Inc. ANTIBODIES BINDING TO AXL PROTEINS
US11136399B2 (en) * 2016-07-14 2021-10-05 Institute Of Biophysics, Chinese Academy Of Sciences Type I interferon receptor antibody and use thereof
MX2022011142A (es) * 2020-03-09 2022-12-13 Abcellera Biologics Inc Anticuerpos anti-coronavirus y metodos de uso.
EP4277926A1 (en) * 2021-01-15 2023-11-22 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies

Similar Documents

Publication Publication Date Title
JP2018525320A5 (cg-RX-API-DMAC7.html)
JP2020522261A5 (cg-RX-API-DMAC7.html)
JP2020500508A5 (cg-RX-API-DMAC7.html)
JP2018516853A5 (cg-RX-API-DMAC7.html)
JP2020526478A5 (cg-RX-API-DMAC7.html)
PH12020551173A1 (en) Anti-pd-l1 antibodies and uses thereof
JP2019527553A5 (cg-RX-API-DMAC7.html)
RU2018108048A (ru) Новые анти-pd-1 антитела
JP2010536384A5 (cg-RX-API-DMAC7.html)
HRP20201928T1 (hr) Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1
NZ601858A (en) Methods and compositions for diagnosis and treatment of amyloidosis
JP2016527225A5 (cg-RX-API-DMAC7.html)
NZ601342A (en) Antibodies that bind il-4 and/or il-13 and their uses
JP2018512379A5 (cg-RX-API-DMAC7.html)
IL273196B2 (en) Claudin6 antibodies and methods of treating cancer
JPWO2020176678A5 (cg-RX-API-DMAC7.html)
JP2020533016A5 (cg-RX-API-DMAC7.html)
JP2013515013A5 (cg-RX-API-DMAC7.html)
RU2011121818A (ru) Способ иммунологического анализа белка cxcl1 человека
NZ598670A (en) Antibodies against glucagon receptor and their use
JP2017521054A5 (cg-RX-API-DMAC7.html)
JP2017524362A5 (cg-RX-API-DMAC7.html)
PE20221511A1 (es) Anticuerpos anti-ly6g6d y metodos de uso
JP2016501877A5 (cg-RX-API-DMAC7.html)
IL250289B2 (en) Antibodies against angiopoietin-like 4 and methods of use